SG11201701506PA - Recombinant modified vaccinia virus ankara (mva) filovirus vaccine - Google Patents
Recombinant modified vaccinia virus ankara (mva) filovirus vaccineInfo
- Publication number
- SG11201701506PA SG11201701506PA SG11201701506PA SG11201701506PA SG11201701506PA SG 11201701506P A SG11201701506P A SG 11201701506PA SG 11201701506P A SG11201701506P A SG 11201701506PA SG 11201701506P A SG11201701506P A SG 11201701506PA SG 11201701506P A SG11201701506P A SG 11201701506PA
- Authority
- SG
- Singapore
- Prior art keywords
- mva
- vaccinia virus
- modified vaccinia
- virus ankara
- recombinant modified
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045538P | 2014-09-03 | 2014-09-03 | |
| US201462055154P | 2014-09-25 | 2014-09-25 | |
| PCT/EP2015/070161 WO2016034678A2 (en) | 2014-09-03 | 2015-09-03 | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201701506PA true SG11201701506PA (en) | 2017-03-30 |
Family
ID=54145734
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201901735XA SG10201901735XA (en) | 2014-09-03 | 2015-09-03 | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
| SG11201701506PA SG11201701506PA (en) | 2014-09-03 | 2015-09-03 | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201901735XA SG10201901735XA (en) | 2014-09-03 | 2015-09-03 | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US10576141B2 (en) |
| EP (1) | EP3188752A2 (en) |
| JP (2) | JP6823586B2 (en) |
| KR (2) | KR20230134155A (en) |
| CN (2) | CN106999565B (en) |
| AU (2) | AU2015310909B2 (en) |
| BR (1) | BR112017003908A2 (en) |
| CA (1) | CA2959105C (en) |
| IL (2) | IL250552B (en) |
| MX (1) | MX2017002791A (en) |
| MY (1) | MY193417A (en) |
| NZ (1) | NZ729012A (en) |
| SG (2) | SG10201901735XA (en) |
| UA (1) | UA126848C2 (en) |
| WO (1) | WO2016034678A2 (en) |
| ZA (1) | ZA201701077B (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| RS58080B1 (en) | 2014-11-04 | 2019-02-28 | Janssen Vaccines & Prevention Bv | Therapeutic hpv16 vaccines |
| EP3682821B1 (en) * | 2014-11-26 | 2022-05-11 | Neuravi Limited | A clot retrieval device for removing an occlusive clot from a blood vessel |
| EP3244919A4 (en) * | 2015-01-12 | 2018-06-27 | Geovax, Inc. | Compositions and methods for generating an immune response to a hemorrhagic fever virus |
| EP3261669B1 (en) * | 2015-02-25 | 2022-08-03 | Memorial Sloan Kettering Cancer Center | Use of inactivated nonreplicating modified vaccinia virus ankara (mva)as monoimmunotherapy or in combination with immune checkpoint blocking agents for solid tumors |
| ES2944314T3 (en) | 2016-01-08 | 2023-06-20 | Geovax Inc | Compositions and methods for generating an immune response against a tumor-associated antigen |
| BR112018015696A2 (en) | 2016-02-03 | 2018-12-26 | Geovax Inc | compositions and methods for generating an immune response to a flavivirus |
| KR20190006495A (en) | 2016-04-15 | 2019-01-18 | 알파인 이뮨 사이언시즈, 인코포레이티드 | CD80 variant immunoregulatory proteins and uses thereof |
| WO2017192418A1 (en) * | 2016-05-02 | 2017-11-09 | Janssen Vaccine & Prevention B.V. | Therapeutic hpv vaccine combinations |
| US10925956B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
| WO2018022945A1 (en) | 2016-07-28 | 2018-02-01 | Alpine Immune Sciences, Inc. | Cd112 variant immunomodulatory proteins and uses thereof |
| AU2017345764A1 (en) * | 2016-10-20 | 2019-05-02 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| AU2018235838B2 (en) | 2017-03-16 | 2023-12-14 | Alpine Immune Sciences, Inc. | CD80 variant immunomodulatory proteins and uses thereof |
| US11732022B2 (en) | 2017-03-16 | 2023-08-22 | Alpine Immune Sciences, Inc. | PD-L2 variant immunomodulatory proteins and uses thereof |
| EP3606553A1 (en) | 2017-04-06 | 2020-02-12 | Janssen Vaccines & Prevention B.V. | Mva-bn and ad26.zebov or ad26.filo prime-boost regimen |
| KR20200003921A (en) | 2017-05-15 | 2020-01-10 | 얀센 백신스 앤드 프리벤션 비.브이. | Stable Virus-Containing Compositions |
| CA3062549A1 (en) * | 2017-05-15 | 2018-11-22 | Janssen Vaccines & Prevention B.V. | Stable virus-containing composition |
| WO2019018501A1 (en) * | 2017-07-18 | 2019-01-24 | Geovax Inc. | Compositions and methods for generating an immune response to lasv |
| US11311612B2 (en) | 2017-09-19 | 2022-04-26 | Geovax, Inc. | Compositions and methods for generating an immune response to treat or prevent malaria |
| GB201716181D0 (en) * | 2017-10-04 | 2017-11-15 | Univ Cape Town | Recombinant mva with modified hiv-1 env |
| EP3694870A1 (en) | 2017-10-10 | 2020-08-19 | Alpine Immune Sciences, Inc. | Ctla-4 variant immunomodulatory proteins and uses thereof |
| EA202090974A1 (en) | 2017-10-18 | 2020-08-05 | Элпайн Иммьюн Сайенсиз, Инк. | VARIANT IMMUNOMODULATING PROTEINS OF ICOS LIGAND AND ACCOMPANYING COMPOSITIONS AND METHODS |
| JP2021533157A (en) * | 2018-08-07 | 2021-12-02 | ウィスコンシン アルムニ リサーチ ファンデイション | Recombinant biologically contained filovirus vaccine |
| CA3111273C (en) | 2018-09-06 | 2024-03-26 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
| WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| WO2021180943A1 (en) | 2020-03-12 | 2021-09-16 | Bavarian Nordic A/S | Compositions improving poxvirus stability |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2350270B1 (en) * | 2008-10-24 | 2018-03-07 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Human ebola virus species and compositions and methods thereof |
| MY161849A (en) * | 2008-11-21 | 2017-05-15 | Bavarian Nordic As | Vector comprising multiple homologous nucleotide sequences |
| EP2473525A4 (en) * | 2009-09-02 | 2013-08-21 | Us Army | Monoclonal antibodies against glycoprotein of ebola sudan boniface virus |
| US9526777B2 (en) | 2010-04-16 | 2016-12-27 | The United States Of America As Represented By The Department Of Health And Human Services | Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein |
| EP4190350A1 (en) | 2012-04-12 | 2023-06-07 | The Trustees Of The University Of Pennsylvania | Filovirus consensus antigens, nucleic acid constructs and vaccines made therefrom, and methods of using same |
| WO2014037124A1 (en) * | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
| GB201303406D0 (en) | 2013-02-26 | 2013-04-10 | Health Prot Agency | Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition |
-
2015
- 2015-09-03 CN CN201580047328.1A patent/CN106999565B/en active Active
- 2015-09-03 WO PCT/EP2015/070161 patent/WO2016034678A2/en active Application Filing
- 2015-09-03 UA UAA201702987A patent/UA126848C2/en unknown
- 2015-09-03 US US15/508,851 patent/US10576141B2/en active Active
- 2015-09-03 CN CN202110238900.XA patent/CN112972668A/en active Pending
- 2015-09-03 MX MX2017002791A patent/MX2017002791A/en unknown
- 2015-09-03 KR KR1020237030452A patent/KR20230134155A/en active Application Filing
- 2015-09-03 BR BR112017003908-7A patent/BR112017003908A2/en active Search and Examination
- 2015-09-03 MY MYPI2017700483A patent/MY193417A/en unknown
- 2015-09-03 JP JP2017510880A patent/JP6823586B2/en active Active
- 2015-09-03 AU AU2015310909A patent/AU2015310909B2/en active Active
- 2015-09-03 KR KR1020177006091A patent/KR20170048396A/en not_active IP Right Cessation
- 2015-09-03 SG SG10201901735XA patent/SG10201901735XA/en unknown
- 2015-09-03 CA CA2959105A patent/CA2959105C/en active Active
- 2015-09-03 EP EP15763853.7A patent/EP3188752A2/en active Pending
- 2015-09-03 SG SG11201701506PA patent/SG11201701506PA/en unknown
- 2015-09-03 NZ NZ729012A patent/NZ729012A/en unknown
-
2017
- 2017-02-12 IL IL250552A patent/IL250552B/en unknown
- 2017-02-13 ZA ZA2017/01077A patent/ZA201701077B/en unknown
-
2020
- 2020-02-27 US US16/802,805 patent/US11338030B2/en active Active
-
2021
- 2021-01-06 JP JP2021000975A patent/JP7113924B2/en active Active
- 2021-07-28 AU AU2021209228A patent/AU2021209228A1/en active Pending
-
2022
- 2022-01-23 IL IL290052A patent/IL290052A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2959105A1 (en) | 2016-03-10 |
| CA2959105C (en) | 2023-10-17 |
| CN106999565A (en) | 2017-08-01 |
| CN106999565B (en) | 2021-03-05 |
| US20170304427A1 (en) | 2017-10-26 |
| IL250552B (en) | 2022-02-01 |
| KR20230134155A (en) | 2023-09-20 |
| MY193417A (en) | 2022-10-12 |
| WO2016034678A2 (en) | 2016-03-10 |
| IL250552A0 (en) | 2017-03-30 |
| KR20170048396A (en) | 2017-05-08 |
| AU2015310909A1 (en) | 2017-03-02 |
| US10576141B2 (en) | 2020-03-03 |
| JP7113924B2 (en) | 2022-08-05 |
| WO2016034678A3 (en) | 2016-06-02 |
| IL290052A (en) | 2022-03-01 |
| UA126848C2 (en) | 2023-02-15 |
| MX2017002791A (en) | 2017-05-30 |
| NZ729012A (en) | 2023-12-22 |
| AU2015310909B2 (en) | 2021-05-27 |
| JP2017527557A (en) | 2017-09-21 |
| AU2021209228A1 (en) | 2021-08-19 |
| CN112972668A (en) | 2021-06-18 |
| JP2021063112A (en) | 2021-04-22 |
| EP3188752A2 (en) | 2017-07-12 |
| US11338030B2 (en) | 2022-05-24 |
| BR112017003908A2 (en) | 2018-02-27 |
| ZA201701077B (en) | 2022-07-27 |
| SG10201901735XA (en) | 2019-03-28 |
| JP6823586B2 (en) | 2021-02-03 |
| US20200268872A1 (en) | 2020-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290052A (en) | Recombinant modified vaccinia virus ankara (mva) filovirus vaccine | |
| HK1246183A1 (en) | Hpv vaccines | |
| PT3718565T (en) | Respiratory virus vaccines | |
| ZA201904717B (en) | Therapeutic hpv18 vaccines | |
| DK3207053T3 (en) | New Immunogenic Peptides | |
| PL3659614T3 (en) | Oncolytic vaccinia virus | |
| GB201518684D0 (en) | Vaccine | |
| PL3407910T3 (en) | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine | |
| IL252512A0 (en) | Stable liquid vaccinia virus formulations | |
| ZA201801091B (en) | Recombinant orf virus vector | |
| ZA201808121B (en) | Therapeutic hpv vaccine combinations | |
| IL247185B (en) | Tilapia lake virus vaccines | |
| GB201522132D0 (en) | Vaccine | |
| IL254698A0 (en) | Recombinant mumps virus jeryl lynn 2 based vaccine | |
| DK3155004T3 (en) | VACCINE FOR IMMUNCOMPROMISED HOSTS | |
| EP3211073A4 (en) | Replicative vaccinia virus vector hiv vaccine | |
| GB201504579D0 (en) | Ovine vaccine | |
| PT3407910T (en) | Recombinant modified vaccinia virus ankara (mva) equine encephalitis virus vaccine | |
| GB201507529D0 (en) | Virus preparations | |
| GB201408046D0 (en) | Virus preparations |